Michael Bishop to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Michael Bishop has written about Antineoplastic Agents, Immunological.
Connection Strength
0.673
-
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):629-639.
Score: 0.625
-
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
Score: 0.048